BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. Source
No articles found.
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse p...
Oncternal Therapeutics is a clinical-stage onco...
Acasti is a biopharmaceutical innovator focused on the research, development and c...
Acasti is a biopharmaceutical innovator focused...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapie...
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)...
Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage neuroscience company f...
Prothena Corporation plc (Nasdaq: PRTA) is a cl...
We are an international biotechnology company that is focused in the field of rege...
We are an international biotechnology company t...
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
Scholar Rock is a biopharmaceutical company focused on the discovery and developme...
Scholar Rock is a biopharmaceutical company foc...
Join the National Investor Network and get the latest information with your interests in mind.